Risk factors

This pre-clinical biotech and AI healthcare company faces severe going concern doubts with only $220,467 in cash as of June 30, 2024, and an accumulated deficit of $325 million. The risk profile is dominated by the heavy capital requirements for unproven gene, cell, and immunotherapy candidates and AI diagnostics. Reputation and business operations have been harmed by the arrest and indictment of co-founder Serhat Gümrükcü.

Sales heavily depend on major customers like Walmart and mature product categories requiring successful new product introductions.

U.S. and Canadian operations drive the majority of sales, with California alone accounting for 27 percent of U.S. sales.

Micron’s risks are dominated by sharp DRAM pricing swings and intense competition in semiconductor memory and storage.

International sales generated 52% of total revenue in fiscal 2024, exposing operations to geopolitical and currency fluctuations.

Concentrated in Kentucky residential real estate loans and exposed to local economic distress in coal-dependent Perry County markets.

Concentrated reliance on a single San Francisco hotel property and market.

Legacy Education relies heavily on federal Title IV student financial aid and must navigate complex Department of Education regulations. Strict compliance standards govern institutional accreditation, financial responsibility, and recruitment compensation across campuses like HDMC, CCC, and Integrity.

Risk factors are heavily weighted toward grocery distribution logistics, customer concentration, and low-margin industry pressures. Debt obligations, labor availability, and IT infrastructure reliability dominate operational concerns.

Amesite faces substantial going concern doubt with net losses of $4.4 million in fiscal 2024. Its new NurseMagic healthcare app is currently not HIPAA compliant. The company relies heavily on a small customer base and college partners to drive revenue.

Biovie is a development-stage biopharmaceutical company with no approved products, commercial revenues, or manufacturing experience.

The company faces going concern doubts after incurring a $6.39 million net loss in fiscal 2024. Customer concentration is high, with five customers generating 53% of fiscal 2024 revenues. Nasdaq compliance is threatened by a closing bid price below $1.00.